NCT05526755 (TARGET) is a Phase 2 clinical trial of Osimertinib 80 mg/40 mg in Stage II-IIIB Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.

Who is sponsoring NCT05526755?

NCT05526755 is sponsored by AstraZeneca.

What drugs are being tested in NCT05526755?

Interventions in NCT05526755: Osimertinib 80 mg/40 mg.

What condition does NCT05526755 study?

NCT05526755 studies Stage II-IIIB Non-small Cell Lung Carcinoma.

Is NCT05526755 still recruiting?

NCT05526755 is currently active, enrolled. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT05526755: TARGET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Active, enrolled Phase 2 Last updated 4 March 2026

What this trial tests

Phase 2 trial testing Osimertinib 80 mg/40 mg in Stage II-IIIB Non-small Cell Lung Carcinoma in 188 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 March 2023

Primary endpoint
22 November 2029

22 November 2029

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	188
Start date	6 March 2023
Primary completion	22 November 2029
Estimated completion	22 November 2029
Sites	56 locations across Hong Kong, Italy, Malaysia, Taiwan, United Kingdom, South Korea, Philippines, Thailand

Drugs / interventions tested

Osimertinib 80 mg/40 mg — full drug profile →

Conditions studied

Stage II-IIIB Non-small Cell Lung Carcinoma — all drugs for Stage II-IIIB Non-small Cell Lung Carcinoma →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Stage II-IIIB Non-small Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS, Wu YL, John T, Grohe C, et al · · 2023 · cited 301× · PMID 36720083 · DOI 10.1200/jco.22.02186
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Herbst RS, John T, Grohé C, Goldman JW, et al · · 2025 · cited 29× · PMID 40097663 · DOI 10.1038/s41591-025-03577-y
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
Soo RA, de Marinis F, Han JY, Ho JC, et al · · 2024 · cited 18× · PMID 37914594 · DOI 10.1016/j.cllc.2023.09.005
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.
Borgeaud M, Olivier T, Bar J, Saw SPL, et al · · 2025 · cited 16× · PMID 40673977 · DOI 10.3322/caac.70024
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies.
Lavaud P, Bortolot M, Zullo L, O'Reilly D, et al · · 2024 · cited 11× · PMID 39199552 · DOI 10.3390/cancers16162779
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Fuorivia V, Attili I, Corvaja C, Asnaghi R, et al · · 2024 · cited 7× · PMID 39330007 · DOI 10.3390/curroncol31090379
Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer.
Kim MH, Kim SH, Lee MK, Eom JS. · · 2024 · cited 7× · PMID 37967564 · DOI 10.4046/trd.2023.0085
A narrative review on perioperative systemic therapy in non-small cell lung cancer.
Hsu R, Arter ZL, Poei D, Benjamin DJ. · · 2024 · cited 3× · PMID 39280253 · DOI 10.37349/etat.2024.00256

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05526755 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05526755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing